Andrea L. Axtell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea L. Axtell has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Derek J. Erstad
Division of Surgical Oncology, Baylor College of Medicine, Houston, TX, United States
8 shared publications - Martin S. Taylor
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
8 shared publications - Michael Lanuti
Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Mass
8 shared publications Akhil Chawla
7 shared publications- Bryan C. Fuchs
Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts
7 shared publications Chloe Jones
7 shared publications
Latest Publications
- Open Access
Artificial Intelligence and the Evolving Paradigm of Lung Cancer Management
Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to late-stage diagnosis, biological heterogeneity, and persistent challenges in staging and treatment selection. This narrative review summarizes current and emerging applications of AI across lung cancer screening and early detection, imaging-based staging and prognostication, tissue and liquid biopsy-based tumor characterization, treatment planning, surgical and intraoperative guidance, and drug discovery. In imaging, deep learning models have demonstrated high performance in pulmonary nodule detection, risk stratification, and prediction of molecular alterations, while also showing promise in improving screening efficiency and reducing interpretive variability. In pathology and liquid biopsy domains, AI enables prediction of driver mutations, immunotherapy response, and survival outcomes directly from histopathology slides, circulating tumor DNA, and other blood-based biomarkers, facilitating minimally invasive precision oncology approaches. In treatment planning and delivery, AI systems are being developed to support clinical decision-making, surgical planning (through advanced image segmentation and delineation of operative anatomy), and intraoperative navigation through robotic and computer vision-enabled platforms. Despite these advances, significant barriers remain, including limited real-world validation, algorithmic biases, workflow integration issues, and unresolved ethical and legal concerns. Future progress will depend on the development of transparent, clinically validated, and generalizable AI systems that augment rather than replace the expertise of clinical providers and healthcare teams. Active engagement from pulmonologists, oncologists, radiologists, and thoracic surgeons will be essential in guiding safe implementation and ensuring that AI-driven innovations translate into meaningful improvements in patient outcomes.
Open AccessArtificial Intelligence and the Evolving Paradigm of Lung Cancer Management
Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to late-stage diagnosis, biological heterogeneity, and persistent challenges in staging and treatment selection. This narrative review summarizes current and emerging applications of AI across lung cancer screening and early detection, imaging-based staging and prognostication, tissue and liquid biopsy-based tumor characterization, treatment planning, surgical and intraoperative guidance, and drug discovery. In imaging, deep learning models have demonstrated high performance in pulmonary nodule detection, risk stratification, and prediction of molecular alterations, while also showing promise in improving screening efficiency and reducing interpretive variability. In pathology and liquid biopsy domains, AI enables prediction of driver mutations, immunotherapy response, and survival outcomes directly from histopathology slides, circulating tumor DNA, and other blood-based biomarkers, facilitating minimally invasive precision oncology approaches. In treatment planning and delivery, AI systems are being developed to support clinical decision-making, surgical planning (through advanced image segmentation and delineation of operative anatomy), and intraoperative navigation through robotic and computer vision-enabled platforms. Despite these advances, significant barriers remain, including limited real-world validation, algorithmic biases, workflow integration issues, and unresolved ethical and legal concerns. Future progress will depend on the development of transparent, clinically validated, and generalizable AI systems that augment rather than replace the expertise of clinical providers and healthcare teams. Active engagement from pulmonologists, oncologists, radiologists, and thoracic surgeons will be essential in guiding safe implementation and ensuring that AI-driven innovations translate into meaningful improvements in patient outcomes.
- Open Access
STAS More than a Prognostic Marker—An Evolving Factor in Operative and Adjuvant Treatment Decisions in Early-Stage NSCLC
Since tumor spread through air spaces (STAS) was first described over a decade ago, numerous studies have demonstrated that it is a high-risk prognostic feature in non-small cell lung cancer (NSCLC). However, due to preoperative and intraoperative limitations in pathologic diagnosis, STAS is generally diagnosed following curative intent resection. While STAS should influence NSCLC treatment strategy—particularly upfront surgical decision-making—postoperative diagnosis of STAS has heretofore limited this possibility. While limited to retrospective studies, the current evidence suggests that patients with tumor STAS should undergo a more extensive anatomical resection—preferably a lobectomy, if they are candidates. These results are particularly important in the setting of the results of the JCOG0802 and CALGB 140503 randomized controlled trials which have begun a paradigm-shift toward sublobar resections for early-stage NSCLC, which may not hold similar benefit for early-stage STAS+ disease. The aims of this review are to: (1) detail the current evidence concerning choice of resection extent for STAS+ disease, (2) summarize the current evidence about optimum surgical margins for STAS+ disease, (3) detail the potential role for adjuvant chemotherapy in early-stage STAS+ disease, (4) assess the current limitations in preoperative STAS risk prediction and intraoperative STAS detection, and (5) highlight promising AI-based advancements which will allow surgeons to risk-stratify STAS probability or confirm STAS status intraoperatively. The main limitation of this review is the reliance on retrospective studies as there is a current lack of prospective or randomized data within STAS+ NSCLC, particularly regarding optimal resection strategy for STAS+ disease.
Open AccessSTAS More than a Prognostic Marker—An Evolving Factor in Operative and Adjuvant Treatment Decisions in Early-Stage NSCLC
Since tumor spread through air spaces (STAS) was first described over a decade ago, numerous studies have demonstrated that it is a high-risk prognostic feature in non-small cell lung cancer (NSCLC). However, due to preoperative and intraoperative limitations in pathologic diagnosis, STAS is generally diagnosed following curative intent resection. While STAS should influence NSCLC treatment strategy—particularly upfront surgical decision-making—postoperative diagnosis of STAS has heretofore limited this possibility. While limited to retrospective studies, the current evidence suggests that patients with tumor STAS should undergo a more extensive anatomical resection—preferably a lobectomy, if they are candidates. These results are particularly important in the setting of the results of the JCOG0802 and CALGB 140503 randomized controlled trials which have begun a paradigm-shift toward sublobar resections for early-stage NSCLC, which may not hold similar benefit for early-stage STAS+ disease. The aims of this review are to: (1) detail the current evidence concerning choice of resection extent for STAS+ disease, (2) summarize the current evidence about optimum surgical margins for STAS+ disease, (3) detail the potential role for adjuvant chemotherapy in early-stage STAS+ disease, (4) assess the current limitations in preoperative STAS risk prediction and intraoperative STAS detection, and (5) highlight promising AI-based advancements which will allow surgeons to risk-stratify STAS probability or confirm STAS status intraoperatively. The main limitation of this review is the reliance on retrospective studies as there is a current lack of prospective or randomized data within STAS+ NSCLC, particularly regarding optimal resection strategy for STAS+ disease.
- 2 May 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 120 (5) , 1008-1009
Anastomotic Leaks After Esophagectomy—Severity and Impact on Quality of Life
- 2 May 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 120 (5) , 1008-1009
Anastomotic Leaks After Esophagectomy—Severity and Impact on Quality of Life
- Open Access
- 13 February 2025
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 3 (3) , 687-692
Sublobar Resection in Stage I Lung Cancer With Tumor Spread Through Air Spaces
- 13 February 2025
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 3 (3) , 687-692
Open AccessSublobar Resection in Stage I Lung Cancer With Tumor Spread Through Air Spaces
- 24 January 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (4) , 796-804
Anastomotic Leak After Esophagectomy: Analysis of the STS General Thoracic Surgery Database
- 24 January 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (4) , 796-804
Anastomotic Leak After Esophagectomy: Analysis of the STS General Thoracic Surgery Database
- 13 August 2024
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 35 (1) , 73-81
Management of Tracheoesophageal Fistula and Tracheoinnominate Fistula
- 13 August 2024
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 35 (1) , 73-81
Management of Tracheoesophageal Fistula and Tracheoinnominate Fistula
- 29 January 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 117 (5) , 998-1005
Predictors of Venous Thromboembolism After Lung Cancer Resection
- 29 January 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 117 (5) , 998-1005
Predictors of Venous Thromboembolism After Lung Cancer Resection
- 3 June 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (3) , 533-541
Association Between Interstitial Lung Disease and Outcomes After Lung Cancer Resection
- 3 June 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (3) , 533-541
Association Between Interstitial Lung Disease and Outcomes After Lung Cancer Resection